Superworth

BIO-TECHNE price to free cash flow TECH

Market value divided by free cash flow over the last twelve months, since 2011.

Today, Nov 2, 2026
43.3×
10-year median
46.2×
Against its 10-year history
38th
percentile: 0 is its lowest day, 100 its highest
10-year range
25.1× to 95.8×
Peer median
22.5×

BIO-TECHNE's price to free cash flow is 43.3× as of Nov 2, 2026.

That is below its ten-year median of 46.2×, close to the middle of its last ten years.

Over that time it ranged from 25.1× in May 2026 to 95.8× in Feb 2021.

The median for 10 biotech stocks of a similar size is 22.5×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far43.3×25.1×47.8×
202541.2×29.9×50.0×
202447.3×43.3×53.9×
202356.6×42.2×60.5×
202245.7×39.6×56.8×
202168.9×60.7×95.8×
202079.9×38.9×80.9×
201955.1×37.6×56.1×
201836.9×35.8×44.4×
201741.4×28.7×41.4×
201630.6×26.9×34.6×
201529.3×26.7×32.5×
201428.1×26.6×34.2×
201333.7×19.8×33.7×
201222.1×19.3×23.3×
201119.8×18.1×21.8×

Against its peers

Companies in Biotechnology nearest BIO-TECHNE's size, closest first, today.

CompanyPrice to free cash flow
TECHBIO-TECHNE43.3×
RGENRepligen87.2×
HALOHalozyme Therapeutics18.2×
NBIXNeurocrine Biosciences17.0×
KRYSKrystal Biotech34.0×
EXELExelixis14.8×
ALNYAlnylam Pharmaceuticals26.7×
INCYIncyte12.7×
UTHRUnited Therapeutics23.7×
ONCBeOne Medicines30.2×
ADMAAdma Biologics21.3×
Peer median22.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on BIO-TECHNE

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.